Today: 8 July 2026
Browse Category

NASDAQ:NUVL 14 January 2026 - 10 June 2026

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent is trading on deal odds now, not on drug data. Shares last traded at $123.25, up 39.28%, after GSK said it will buy the Nasdaq-listed biotech for $124 per share in cash. That leaves just a small discount to the offer price. Nuvalent’s stock is being valued more like a GSK takeover play than an oncology bet. Nuvalent stock got a new cap Tuesday after the company agreed to a buyout. GSK said it will make a tender offer for all outstanding Class A and Class B shares at $124 each, within 10 business days. Tender offers pay cash straight to shareholders and are often used to speed up takeovers. The $124 offer is 40% over Nuvalent’s previous close and 26% above its 30-day volume-weighted average price, which tracks average trading prices by volume.
10 June 2026
····
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

Dow, S&P 500 edge up, Nasdaq slips in midday trade U.S. stocks were mixed late Tuesday morning. The Dow and S&P 500 held small gains, while the Nasdaq slipped after a rebound in artificial-intelligence shares and ahead of another inflation readout this week. Delayed LSEG data from Reuters showed the S&P 500 up 0.22% at 7,421.81, the Dow up 0.30% at 50,940.88, and the Nasdaq down 0.03% at 25,921.29. Wall Street is looking to recover after tech stocks dropped hard late last week. Now investors are waiting for May’s Consumer Price Index from the Labor Department, expected at 8:30 a.m. EDT Wednesday.
9 June 2026
·········
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK is set to acquire U.S.-based Nuvalent for $10.6 billion in cash, making it the largest deal GSK has made in years. The offer is $124 per share, which works out to a 40% premium on Nuvalent’s previous closing price. It’s an early move by CEO Luke Miels as he looks to revamp the British group’s oncology pipeline. GSK is looking for late-stage drugs as it braces for patent expiry on dolutegravir, its main HIV therapy, between 2028 and 2030. After that, cheaper products could hit sales. Nuvalent could bring in new revenue as early as 2027 and give GSK a shot at keeping annual sales above 40 billion pounds by 2031.
9 June 2026
··

Stock Market Today

  • S&P/TSX Composite Sinks 600+ Points as Trump Calls Off Iran Ceasefire
    July 8, 2026, 12:13 PM EDT. The S&P/TSX composite index lost 626.71 points to finish at 34,645.88 as geopolitical jitters intensified. President Donald Trump said the Iran ceasefire had ended after Iranian attacks on commercial ships. U.S. markets took a hit too: the Dow shed 776.20 points, the S&P 500 dropped 71.63 points. Oil jumped $5.18 to $75.62 a barrel on supply fears. The Canadian dollar moved up slightly, reaching 70.53 U.S. cents. Investors reacted to U.S. military strikes in Iran and signs that more action could be coming.
Go toTop